[Pubmed] Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6507
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Chrome

[Pubmed] Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending

Message par RSS-Bot »


Front Immunol. 2025 Nov 28;16:1671964. doi: 10.3389/fimmu.2025.1671964. eCollection 2025.

ABSTRACT

Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare yet life-threatening immune-related adverse event (irAE), whose management is even more challenging when complicated by an impending crisis of myasthenia gravis (MG). This article presents a case of a 69-year-old woman with bladder malignancy, coexisting MG, diabetes, hypertension, and coronary artery disease. On day 16 after tislelizumab (PD-1 inhibitor) therapy, she exhibited aggravated MG symptoms, with an impending crisis, alongside asymptomatic ICI-associated myocarditis. Clinical manifestations included generalized fatigue, anorexia, bilateral ptosis, dysarthria, neck and limb weakness, shortness of breath, and dyspnea. Laboratory tests revealed elevated troponin T, troponin I, creatine kinase (CK), creatine kinase-myocardial band (CK-MB), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels, suggesting a diagnosis of ICI-associated myocarditis and liver injury. Doppler ultrasound indicated thrombosis in the left calf muscle space. Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. Treatment with prednisone acetate (60 mg once daily) resulted in gradual reductions in myocardial enzymes, troponins, and transaminases. Efgartigimod demonstrated notable efficacy as salvage therapy for ICI-associated myocarditis, myositis, liver injury, and impending crisis of MG. Early recognition and tailored treatment strategies are crucial for improving patient outcomes in such complex cases.

PMID:41394836 | PMC:PMC12698593 | DOI:10.3389/fimmu.2025.1671964


Source: https://pubmed.ncbi.nlm.nih.gov/4139483 ... 22+67771e2
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »